Premium
Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital
Author(s) -
Calandre E. P.,
RodriguezLopez C.,
Blazquez A.,
Cano D.
Publication year - 1991
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1991.tb04691.x
Subject(s) - carbamazepine , phenobarbital , valproic acid , apolipoprotein b , medicine , endocrinology , cholesterol , epilepsy , anticonvulsant , chemistry , blood lipids , psychiatry
Serum lipids, lipoproteins and apolipoproteins A and B were measured in 101 epileptic patients receiving chronic treatment with valproic acid, carbamazepine or phenobarbital and in 75 age‐ and sex‐matched control subjects. In relation to controls, subjects treated with valproic acid showed significantly lower values of total and LDL‐cholesterol levels; subjects treated with carbamazepine showed significantly higher values of HDL‐cholesterol and apolipoprotein A concentrations and subjects treated with phenobarbital showed significantly higher values of total cholesterol, HDL‐cholesterol, apolipoprotein A and apolipoprotein B levels. The total cholesterol/HDL‐cholesterol ratio was significantly lower in patients receiving valproic acid or carbamazepine but not in the phenobarbital‐treated group. Changes in serum lipids profile did not correlate with drug plasma concentrations nor the duration of the treatment.